Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Johnson and Johnson
Johnson and Johnson
Activities:
Research & Development
Medical Devices
Pharmaceutical
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Marketing
Janssen to adopt Johnson & Johnson brand as the company celebrates 100 years of UK operation
The company's pharmaceutical and medical technology segments will combine under the Johnson & Johnson brand name in the UK
Regulatory
FDA grants approval for Johnson & Johnson's antibody for treatment of myeloma
Johnson & Johnson have received accelerated approval of TALVEY, a first-in-class bispecific antibody. TALVEY is a bispecific T-cell engaging antibody that binds to the CD3 receptor
Manufacturing
First-line treatment for patients with metastatic castration-resistant prostate cancer
A company has submitted an NDA for niraparib in combination with abiraterone acetate, in the form of a dual-action tablet (DAT)
Research & Development
F-star Therapeutics announces license agreement with Janssen
The agreement grants Janssen an exclusive license to research, develop, and commercialise bispecific antibodies directed to its therapeutic targets using F-star’s proprietary Fcab and mAb2 platforms
Research & Development
BioMed X and Janssen R&D announce two research groups
The groups will explore research related to autoimmunity and drug delivery
Ingredients
Therapeutic: nipocalimab for myasthenia gravis
The chronic autoimmune disease, myasthenia gravis, affects the skeletal muscles responsible for eye movements, breathing and motion
Research & Development
BioMed X begins research project for oral therapeutics delivery
The collaboration with Janssen Research and Development was facilitated by Johnson & Johnson Innovation
Subscribe now